A large variety of model systems are used in hepatobiliary research. In this review, we aim to provide an overview of established and emerging models for specific research questions. We specifically discuss the value and limitations of these models for research on metabolic associated fatty liver disease (MAFLD), (previously named non-alcoholic fatty liver diseases/non-alcoholic steatohepatitis (NAFLD/NASH)) and cholestasis-related diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The entire range of models is discussed varying from immortalized cell lines, mature or pluripotent stem cell-based models including organoids/spheroids, to animal models and human ex vivo models such as normothermic machine perfusion of livers and living liver slices. Finally, the pros and cons of each model are discussed as well as the need in the scientific community for continuous innovation in model development to better mimic the human (patho)physiology.

Additional Metadata
Keywords Animal models, Cholestasis, MAFLD, NAFLD, NASH, Organoids
Persistent URL dx.doi.org/10.1016/j.bcp.2020.114173, hdl.handle.net/1765/129382
Journal Biochemical Pharmacology
Citation
Kunst, R.F. (Roni F.), Niemeijer, M. (Marije), van der Laan, L.J.W, Spee, B, & van de Graaf, S.F.J. (Stan F.J.). (2020). From fatty hepatocytes to impaired bile flow: Matching model systems for liver biology and disease. Biochemical Pharmacology (Vol. 180). doi:10.1016/j.bcp.2020.114173